These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
346 related items for PubMed ID: 17996339
1. Cost-utility of universal hepatitis A vaccination in Canada. Bauch CT, Anonychuk AM, Pham BZ, Gilca V, Duval B, Krahn MD. Vaccine; 2007 Dec 12; 25(51):8536-48. PubMed ID: 17996339 [Abstract] [Full Text] [Related]
4. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation. Tilson L, Thornton L, O'Flanagan D, Johnson H, Barry M. Eur J Public Health; 2008 Jun 12; 18(3):275-82. PubMed ID: 18160389 [Abstract] [Full Text] [Related]
7. Cost-benefit analysis of hepatitis a vaccination in Thailand. Teppakdee A, Tangwitoon A, Khemasuwan D, Tangdhanakanond K, Suramaethakul N, Sriratanaban J, Poovorawan Y. Southeast Asian J Trop Med Public Health; 2002 Mar 12; 33(1):118-27. PubMed ID: 12118439 [Abstract] [Full Text] [Related]
9. An economic analysis of different strategies of immunization against hepatitis A virus in developed countries. Das A. Hepatology; 1999 Feb 12; 29(2):548-52. PubMed ID: 9918934 [Abstract] [Full Text] [Related]
10. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C viral infection in the United States. Arguedas MR, Heudebert GR, Fallon MB, Stinnett AA. Am J Gastroenterol; 2002 Mar 12; 97(3):721-8. PubMed ID: 11922569 [Abstract] [Full Text] [Related]
11. Pharmaco-economic evaluation of targeted hepatitis A vaccination for children of ethnic minorities in Amsterdam (The Netherlands). Postma MJ, Bos JM, Beutels P, Schilthuis H, van den Hoek JA. Vaccine; 2004 May 07; 22(15-16):1862-7. PubMed ID: 15121296 [Abstract] [Full Text] [Related]
12. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Melegaro A, Edmunds WJ. Vaccine; 2004 Oct 22; 22(31-32):4203-14. PubMed ID: 15474710 [Abstract] [Full Text] [Related]
13. Cost-effectiveness of routine childhood vaccination for hepatitis A in the United States. Rein DB, Hicks KA, Wirth KE, Billah K, Finelli L, Fiore AE, Hoerger TJ, Bell BP, Armstrong GL. Pediatrics; 2007 Jan 22; 119(1):e12-21. PubMed ID: 17200237 [Abstract] [Full Text] [Related]
14. Cost-effectiveness of universal childhood hepatitis A vaccination in Chile. Valenzuela MT, Jacobs RJ, Arteaga O, Navarrete MS, Meyerhoff AS, Innis BL. Vaccine; 2005 Jul 14; 23(32):4110-9. PubMed ID: 15964479 [Abstract] [Full Text] [Related]
15. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis. De Wals P, Coudeville L, Trottier P, Chevat C, Erickson LJ, Nguyen VH. Vaccine; 2007 Jul 20; 25(29):5433-40. PubMed ID: 17560695 [Abstract] [Full Text] [Related]
16. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence. Hung HF, Chen TH. Vaccine; 2009 Nov 12; 27(48):6770-6. PubMed ID: 19735755 [Abstract] [Full Text] [Related]
17. [Cost-benefit analysis for hepatitis A vaccine]. Chen E, Yao J, Yang J. Zhonghua Liu Xing Bing Xue Za Zhi; 1999 Aug 12; 20(4):224-7. PubMed ID: 10682501 [Abstract] [Full Text] [Related]